Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAT2 | Q10469 | 1/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 7/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14331578 | 0.94 | MGAT2 (0.38) | MGAT2G6PDMETAP2CYP11B1CYP11B2 | |
| SCHEMBL14330549 | 0.93 | MGAT2 (0.35) | MGAT2G6PDMETAP2CYP11B1CYP11B2 | |
| SCHEMBL14331577 | 0.86 | MGAT2 (0.38) | MGAT2G6PDMETAP2CYP11B1CYP11B2 | |
| SCHEMBL14330499 | 0.83 | TOP1 (0.38) | G6PDMETAP2HPGDTSHR | |
| SCHEMBL14330589 | 0.81 | DYRK1A (0.37) | DYRK1A | |
| SCHEMBL14329637 | 0.79 | CYP19A1 (0.41) | G6PDCYP3A4HPGD | |
| SCHEMBL14331114 | 0.78 | CDK4 (0.42) | G6PDCYP11B1CYP11B2CYP3A4DYRK1A | |
| SCHEMBL14330586 | 0.78 | DYRK1A (0.36) | CYP11B1CYP11B2CYP17A1CYP3A4HPGD | |
| SCHEMBL14330575 | 0.78 | CDK4 (0.35) | METAP2DYRK1A | |
| SCHEMBL14330566 | 0.78 | GPBAR1 (0.34) | METAP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623521-B2 | Heterocyclic compound and organic light-emitting diode and flat display device including the heterocyclic compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-01-07 | — | — | US | disclosed |
| US-20120326134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120326134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | DDT, DRD1, HTR3D | MGAT2 2806/4885G6PD 716/4885METAP2 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.